Merck’s shot protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease and a lung infection called pneumonia.
The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia.
Some analysts view the jab as a key growth driver for Merck as it prepares to offset losses from its blockbuster cancer drug Keytruda.that can spread to other parts of the body and lead to pneumonia. It's the first pneumococcal conjugate vaccine designed specifically for adults and aims to provide broader protection than theHealthy adults can suffer from pneumococcal disease.
Around 150,000 U.S. adults are hospitalized with invasive pneumococcal disease each year, Platt said. Death from the more serious form of the disease is highest among adults 50 and above, Merck said in aEven after the FDA approval, the company's single-dose vaccine won't reach patients just yet.
"We do expect there to be rapid uptake of" Capvaxive, she said, adding that the company is confident that data on the shot will"really resonate" with clinicians and policymakers.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And MerckRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Baca lebih lajut »
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conferenceCNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
Baca lebih lajut »
Moderna, Merck say vaccine improved survival in patients with deadly skin cancerNearly 75% of patients who took the cancer vaccine and Keytruda were alive without any signs or symptoms of their cancer returning at the 2½-year mark.
Baca lebih lajut »
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rateModerna, Merck shares rise as combined melanoma therapy shows improved survival rate
Baca lebih lajut »
Merck to acquire eye drug company EyeBio for up to $3 billionMerck to acquire eye drug company EyeBio for up to $3 billion
Baca lebih lajut »
Coffee Recall Update as FDA Sets Concern LevelTexas-based firm Waco Bottling LLC has called back 321 cases of 3,852 bottles of its coffee concentrate .
Baca lebih lajut »